Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 61

Sort by

Sort Order Select

Journal Articles

Clinical Implications of p53 Dysfunction in Patients with Myelodysplastic Syndromes

Blood (2022) 140 (Supplement 1): 4001–4004.

https://doi.org/10.1182/blood-2022-166050

Published: 2022

Journal Articles

Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes

Blood (2022) 140 (Supplement 1): 1121–1124.

https://doi.org/10.1182/blood-2022-163634

Published: 2022

Journal Articles

Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS

Maria Sirenko, Elsa Bernard, David B. Beck, Maria Creignou, Dylan Domenico, Andrea Farina, Juan E Arango, Olivier Kosmider, Robert P. Hasserjian, Martin Jadersten, Ulrich Germing, Guillermo Sanz, Arjan A. van de Loosdrecht, Matilde Y Follo, Felicitas R. Thol, Lurdes Zamora, Ronald Feitosa Pinheiro, Andrea Pellagatti, Harold K. Elias, Detlef Haase, Christina Ganster, Lionel Ades, Magnus Tobiasson, Laura Palomo, Matteo G. Della Porta, Kety Huberman, Pierre Fenaux, Monika Belickova, Michael R. Savona, Virginia M. Klimek, Fabio Pires de Souza Santos, Jacqueline Boultwood, Ioannis Kotsianidis, Valeria Santini, Francesc Solé, Uwe Platzbecker, Michael Heuser, Peter Valent, Carlo Finelli, Maria Teresa Voso, Lee-Yung Shih, Seishi Ogawa, Michaela Fontenay, Joop H. Jansen, Jose Cervera, Benjamin L. Ebert, Rafael Bejar, Peter L Greenberg, Norbert Gattermann, Luca Malcovati, Mario Cazzola, Eva Hellström-Lindberg, Elli Papaemmanuil

Blood (2022) 140 (Supplement 1): 9785–9788.

https://doi.org/10.1182/blood-2022-162397

Published: 2022

Journal Articles

Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories

Blood (2022) 140 (Supplement 1): 6976–6978.

https://doi.org/10.1182/blood-2022-158671

Published: 2022

Journal Articles

A Population-Based Study on Survival of Higher Risks Myelofibrosis Patients Treated with Ruxolitinib in the Italian Lombardy Region

Barbara Mora, Giacomo Pellegrini, Matteo Franchi, Margherita Maffioli, Marco Brociner, Paola Guglielmelli, Maria Teresa Voso, Tiziana Ottone, Marta Ubezio, Giulia Maggioni, Michele Merli, Alessandro M. Vannucchi, Matteo G. Della Porta, Giovanni Corrao, Francesco Passamonti

Blood (2022) 140 (Supplement 1): 9737–9739.

https://doi.org/10.1182/blood-2022-164575

Published: 2022

Journal Articles

Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration

Blood (2022) 140 (Supplement 1): 6053–6055.

https://doi.org/10.1182/blood-2022-165088

Published: 2022

Journal Articles

Synthetic Data Generation By Artificial Intelligence to Accelerate Translational Research and Precision Medicine in Hematological Malignancies

Blood (2022) 140 (Supplement 1): 9744–9746.

https://doi.org/10.1182/blood-2022-168646

Published: 2022

Journal Articles

Multi-Modal Analysis and Federated Learning Approach for Classification and Personalized Prognostic Assessment in Myeloid Neoplasms

Blood (2022) 140 (Supplement 1): 9828–9830.

https://doi.org/10.1182/blood-2022-166802

Published: 2022

Journal Articles

Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 1705–1707.

https://doi.org/10.1182/blood-2022-157393

Published: 2022

Journal Articles

Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS)

Luca Lanino, Prassede Salutari, Alessandra Perego, Bruno Fattizzo, Marta Riva, Marta Ubezio, Pellegrino Musto, Daniela Cilloni, Esther Natalie Oliva, Maria Teresa Voso, Anna Maria Pelizzari, Antonella Poloni, Isabella Capodanno, Chiara Elena, Claudio Fozza, Fabrizio Pane, Massimo Breccia, Marco De Gobbi, Francesco Di Bassiano, Daniela Barraco, Elena Crisà, Dario Ferrero, Chiara Frairia, Antonella Vaccarino, Davide Griguolo, Stefania Paolini, Martina Quintini, Mariarosaria Sessa, Mauro Turrini, Monica Bocchia, Nicola Di Renzo, Elisa Diral, Cristina Foli, Alfredo Molteni, Ubaldo Occhini, Giulia Rivoli, Carmine Selleri, Roberto Bono, Anna Calvisi, Andrea Castelli, Eros Di Bona, Ambra Di Veroli, Luana Fianchi, Sara Galimberti, Daniele Grimaldi, Monia Marchetti, Marianna Norata, Alessandro Rambaldi, Ilaria Tanasi, Patrizia Tosi, Ilaria Naldi, Valeria Santini, Matteo G. Della Porta

Blood (2022) 140 (Supplement 1): 6945–6948.

https://doi.org/10.1182/blood-2022-164559

Published: 2022

Journal Articles

Clinical relevance of clonal hematopoiesis in persons aged ≥80 years

Marianna Rossi, Manja Meggendorfer, Matteo Zampini, Mauro Tettamanti, Emma Riva, Erica Travaglino, Matteo Bersanelli, Sara Mandelli, Alessia Antonella Galbussera, Ettore Mosca, Elena Saba, Chiara Chiereghin, Nicla Manes, Chiara Milanesi, Marta Ubezio, Lucio Morabito, Clelia Peano, Giulia Soldà, Rosanna Asselta, Stefano Duga, Carlo Selmi, Maria De Santis, Karolina Malik, Giulia Maggioni, Marilena Bicchieri, Alessia Campagna, Cristina A. Tentori, Antonio Russo, Efrem Civilini, Paola Allavena, Rocco Piazza, Giovanni Corrao, Claudia Sala, Alberto Termanini, Laura Giordano, Paolo Detoma, Aurelio Malabaila, Luca Sala, Stefano Rosso, Roberto Zanetti, Claudia Saitta, Elena Riva, Gianluigi Condorelli, Francesco Passamonti, Armando Santoro, Francesc Sole, Uwe Platzbecker, Pierre Fenaux, Niccolò Bolli, Gastone Castellani, Wolfgang Kern, George S. Vassiliou, Torsten Haferlach, Ugo Lucca, Matteo G. Della Porta

Blood (2021) 138 (21): 2093–2105.

https://doi.org/10.1182/blood.2021011320

Published: 2021

Includes: Supplemental data

Journal Articles

Single Cell Mutation Analysis Delineates Clonal Architecture in Leukemic Transformation of Myeloproliferative Neoplasms

Paola Guglielmelli, Laura Calabresi, Chiara Carretta, Giada Rotunno, Sandra Parenti, Simone Romagnoli, Selene Mallia, Niccolò Bartalucci, Sebastiano Rontauroli, Chiara Chiereghin, Sara Castellano, Francesco Mannelli, Matteo G. Della Porta, Rossella Manfredini, Alessandro Vannucchi

Blood (2021) 138 (Supplement 1): 56.

https://doi.org/10.1182/blood-2021-148315

Published: 2021

Journal Articles

ELN IMDS Flow Working Group Validation of the Monocyte Assay for Chronic Myelomonocytic Leukemia Diagnosis By Flow Cytometry

Orianne Wagner-Ballon, Peter Bettelheim, Jeroen Lauf, Frauke Bellos, Matteo G. Della Porta, Erica Travaglino, Dolores Subirá, Irene Nuevo, Sihem Tarfi, Theresia M. Westers, Ulrika Johansson, Katherina Psarra, Serafeim Karathanos, Sergio Matarraz, Enrique Colado, Monali Gupta, Robin M. Ireland, Wolfgang Kern, Arjan van de Loosdrecht

Blood (2021) 138 (Supplement 1): 2602.

https://doi.org/10.1182/blood-2021-145159

Published: 2021

Journal Articles

MGUS and Chip: Two Faces, but Not of the Same Medal

Matteo Claudio Da Via, Marta Lionetti, Antonio Matera, Erica Travaglino, Ugo Lucca, Emma Riva, Mauro Tettamanti, Luca Baldini, Antonino Neri, Matteo G. Della Porta, Niccolo Bolli

Blood (2021) 138 (Supplement 1): 3800.

https://doi.org/10.1182/blood-2021-147890

Published: 2021

Journal Articles

Cdx Report Program: Heterogeneity Revealed in Current Reporting Practices for Hemato-Oncology Companion Diagnostic (CDx) Markers in Multiple Countries

Sabit Delic, PhD, Piers Blombery, MBBS, María José Calasanz, PhD, Devon S. Chabot-Richards, MD, Dolors Colomer, PhD, Matteo G Della Porta, MD, Paul A S Evans, PhD, Torsten Haferlach, MD, Joanne Mason, FRCPath, Jay L Patel, MD, William S. Stevenson, MBBS, PhD, Christian Thiede, MD, Maria Teresa Voso, MD, Jordan Clark

Blood (2019) 134 (Supplement_1): 5837.

https://doi.org/10.1182/blood-2019-128652

Published: 2019

Journal Articles

SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts

Blood (2015) 126 (2): 233–241.

https://doi.org/10.1182/blood-2015-03-633537

Published: 2015

Includes: Supplemental data

Journal Articles

Diagnostic Application of Immunophenotypic Analysis of Erythroid Dysplasia in Myelodysplastic Syndromes. a Report on Behalf of the European Leukemianet-IMDS-Flow Cytometry Working Group

Theresia M Westers, PhD, Eline MP Cremers, MD, Uta Oelschlaegel, PhD, Ulrika Johansson, PhD, Peter Bettelheim, MD, Birgit Witte, PhD, Matteo G Della Porta, MD, Wolfgang Kern, MD, Arjan van de Loosdrecht, MDPhD

Blood (2014) 124 (21): 1914.

https://doi.org/10.1182/blood.V124.21.1914.1914

Published: 2014

Journal Articles

Somatic Mutations of ASXL1 , RUNX1 and SETBP1 Improve Prognostic Stratification of Patients with Chronic Myelomonocytic Leukemia

Chiara Elena, MD, Anna Gallì, PhD, Esperanza Such, PhD, Ulrich Germing, Ettore Rizzo, PhD, Jose Cervera, MD, Elisabetta Molteni, PhD, Esther Schuler, Ilaria Ambaglio, MD, Maria Lopez-Pavia, Silvia Zibellini, PhD, Andrea Kuendgen, MD, Erica Travaglino, Reyes Sancho-Tello, Matteo G Della Porta, MD, Ana Isabel Vicente, Guillermo F. Sanz, MD PhD, Luca Malcovati, MD, Mario Cazzola, MD

Blood (2014) 124 (21): 1915.

https://doi.org/10.1182/blood.V124.21.1915.1915

Published: 2014

Journal Articles

Genetic Determinants of Disease Phenotype and Clinical Outcome in Myelodysplastic Syndromes with Ring Sideroblasts

Blood (2014) 124 (21): 825.

https://doi.org/10.1182/blood.V124.21.825.825

Published: 2014

Journal Articles

Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia

Blood (2014) 124 (9): 1513–1521.

https://doi.org/10.1182/blood-2014-03-560227

Published: 2014

Includes: Supplemental data

NARROW

Clinical Implications of p53 Dysfunction in Patients with Myelodysplastic Syndromes

Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes

Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS

Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories

A Population-Based Study on Survival of Higher Risks Myelofibrosis Patients Treated with Ruxolitinib in the Italian Lombardy Region

Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration

Synthetic Data Generation By Artificial Intelligence to Accelerate Translational Research and Precision Medicine in Hematological Malignancies

Multi-Modal Analysis and Federated Learning Approach for Classification and Personalized Prognostic Assessment in Myeloid Neoplasms

Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Clinical relevance of clonal hematopoiesis in persons aged ≥80 years

Single Cell Mutation Analysis Delineates Clonal Architecture in Leukemic Transformation of Myeloproliferative Neoplasms

ELN IMDS Flow Working Group Validation of the Monocyte Assay for Chronic Myelomonocytic Leukemia Diagnosis By Flow Cytometry

MGUS and Chip: Two Faces, but Not of the Same Medal

Cdx Report Program: Heterogeneity Revealed in Current Reporting Practices for Hemato-Oncology Companion Diagnostic (CDx) Markers in Multiple Countries

SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts

Diagnostic Application of Immunophenotypic Analysis of Erythroid Dysplasia in Myelodysplastic Syndromes. a Report on Behalf of the European Leukemianet-IMDS-Flow Cytometry Working Group

Somatic Mutations of ASXL1 , RUNX1 and SETBP1 Improve Prognostic Stratification of Patients with Chronic Myelomonocytic Leukemia

Genetic Determinants of Disease Phenotype and Clinical Outcome in Myelodysplastic Syndromes with Ring Sideroblasts

Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only